Overview: Neuron-Specific Enolase TestIntroduction: The Neuron-Specific Enolase Test measures NSE to diagnose neuroendocrine tumors or brain injury, causing pain or confusion. Aligned with 2023 NCCN guidelines, it uses immunoassay for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected neuroendocrine tumors or traumatic brain injury.
Other Names: NSE Assay, Neuroendocrine Tumor Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: NSE testing began in the 1980s with neuroendocrine research. Immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures NSE to diagnose neuroendocrine tumors or brain injury, guides treatment, and evaluates patients with pain or confusion.
Test Parameters: 1. Neuron Specific Enolase
Pretest Condition: No fasting required. Collect serum, plasma, or CSF. Report history of pain, confusion, or neuroendocrine symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL), CSF (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document pain, confusion, weight loss, or history of neuroendocrine tumors. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, neuroendocrine tumor or brain injury implications, and risks of sample collection.
Procedural Considerations: Uses immunoassay to measure NSE in serum, plasma, or CSF. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for neuroendocrine tumor diagnosis.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. CSF collection errors may reduce accuracy.
Clinical Significance: Elevated NSE suggests neuroendocrine tumors or brain injury, guiding treatment (e.g., chemotherapy or supportive care). Normal levels may require further testing.
Specialist Consultation: Consult an oncologist or neurologist for result interpretation and treatment planning.
Additional Supporting Tests: Chromogranin A, brain MRI, or CT to confirm neuroendocrine tumor or brain injury diagnosis.
Test Limitations: Not specific to one condition; other tumors or injuries may elevate NSE. Clinical correlation is needed.
References: NCCN Neuroendocrine Tumor Guidelines, 2023; Journal of Clinical Oncology, Baudin E, 2022.
